

## References

## 7 References

1. Conget I. [Diagnosis, classification and pathogenesis of diabetes mellitus]. *Rev Esp Cardiol.* 2002; 55(5):528-35.
2. World Health Organization. 1999.
3. World Health Organization. 2018.
4. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. *Diabetes Res Clin Pract.* 2019; 157:107843.
5. Blas E, Sivasankara Kurup A, World Health O. In: *Equity, social determinants and public health programmes / editors Erik Blas and Anand Sivasankara Kurup.* 2010. Geneva: World Health Organization.
6. Neha N, Sweata RR. A study on the development of probiotic diabetic Kulfi Indian Ice cream. *Int J Food Sci.* 2018; 3(1):60-64.
7. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. *Endocrinol Metab Clin North Am.* 2010; 39(3):481-97.
8. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. *Nature.* 2010; 464(7293):1293-300.
9. American Diabetes Association. 2014.
10. Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. *World J Diabetes.* 2015; 6(6):850-67.
11. Olefsky J, Farquhar JW, Reaven G. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. *Diabetes.* 1973; 22(7):507-13.
12. Ginsberg H, Kimmerling G, Olefsky JM, Reaven GM. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. *J Clin Invest.* 1975; 55(3):454-61.
13. Kraemer FB, Ginsberg HN, Gerald M, Reaven, MD: Demonstration of the central role of insulin resistance in type 2 diabetes and cardiovascular disease. *Diabetes Care.* 2014; 37(5):1178-81.

14. Wondifraw H. Classification, Pathophysiology, Diagnosis and Management of Diabetes Mellitus. *Journal of Diabetes & Metabolism*. 2015; 06.
15. American Diabetes Association. 2009.
16. Galtier F. Definition, epidemiology, risk factors. *Diabetes Metab*. 2010; 36(6 Pt 2):628-51.
17. Bishay RH, Greenfield JR. A review of maturity onset diabetes of the young (MODY) and challenges in the management of glucokinase-MODY. *Med J Aust*. 2016; 205(10):480-485.
18. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. *Diabetologia*. 2001; 44(8):929-45.
19. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. *Diabetologia*. 2003; 46(1):3-19.
20. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. *Lancet*. 2005; 365(9467):1333-46.
21. Pratley RE. The early treatment of type 2 diabetes. *Am J Med*. 2013; 126(9 Suppl 1):S2-9.
22. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes*. 2003; 52(1):102-10.
23. DeFronzo RA, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, et al. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. *Diabetologia*. 2010; 53(3):435-45.
24. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. *Diabetes*. 2004; 53 Suppl 3:S190-6.
25. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet*. 2006; 368(9548):1696-705.
26. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. *J Clin Endocrinol Metab*. 1986; 63(2):492-8.

27. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. *Endocrinology*. 2002; 143(11):4397-408.
28. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. *Endocrinology*. 2003; 144(12):5149-58.
29. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. *Lancet*. 2002; 359(9309):824-30.
30. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? *Diabetologia*. 2011; 54(1):10-8.
31. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002; 346(6):393-403.
32. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care*. 1997; 20(4):537-44.
33. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001; 344(18):1343-50.
34. Rizkalla SW, Taghrid L, Laromiguiere M, Huet D, Boillot J, Rigoir A, et al. Improved plasma glucose control, whole-body glucose utilization, and lipid profile on a low-glycemic index diet in type 2 diabetic men: a randomized controlled trial. *Diabetes Care*. 2004; 27(8):1866-72.
35. Mahler RJ, Adler ML. Clinical review 102: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. *J Clin Endocrinol Metab*. 1999; 84(4):1165-71.
36. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. *Front Endocrinol (Lausanne)*. 2017; 8:6.
37. International Diabetes Federation. 2019.
38. Frank RN. Diabetic retinopathy. *N Engl J Med*. 2004; 350(1):48-58.

39. Hirai FE, Tielsch JM, Klein BE, Klein R. Ten-year change in vision-related quality of life in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. *Ophthalmology*. 2011; 118(2):353-8.
40. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. *Diabetes Care*. 2011; 34(10):2220-4.
41. Selvarajah D, Wilkinson ID, Emery CJ, Harris ND, Shaw PJ, Witte DR, et al. Early involvement of the spinal cord in diabetic peripheral neuropathy. *Diabetes Care*. 2006; 29(12):2664-9.
42. Wessels AM, Rombouts SA, Simsek S, Kuijjer JP, Kostense PJ, Barkhof F, et al. Microvascular disease in type 1 diabetes alters brain activation: a functional magnetic resonance imaging study. *Diabetes*. 2006; 55(2):334-40.
43. Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum? *Indian J Endocrinol Metab*. 2016; 20(4):546-51.
44. Gilbertson DT, Liu J, Xue JL, Louis TA, Solid CA, Ebben JP, et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. *J Am Soc Nephrol*. 2005; 16(12):3736-41.
45. Rosolova H, Petrlova B, Simon J, Sifalda P, Sipova I, Sefrna F. [Macrovascular and microvascular complications in type 2 diabetes patients]. *Vnitr Lek*. 2008; 54(3):229-37.
46. Campbell LA, Rosenfeld ME. Infection and Atherosclerosis Development. *Arch Med Res*. 2015; 46(5):339-50.
47. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. *Diabetes Care*. 2007; 30(3):734-43.
48. Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. *Aliment Pharmacol Ther*. 2005; 22 Suppl 2:24-7.
49. Pazhanivel M, Jayanthi V. Diabetes mellitus and cirrhosis liver. *Minerva Gastroenterol Dietol*. 2010; 56(1):7-11.
50. Lam YY, Ravussin E. Analysis of energy metabolism in humans: A review of methodologies. *Mol Metab*. 2016; 5(11):1057-1071.

51. Balcer LJ, Liu GT, Forman S, Pun K, Volpe NJ, Galetta SL, et al. Idiopathic intracranial hypertension: relation of age and obesity in children. *Neurology*. 1999; 52(4):870-2.
52. Field AE, Camargo CA, Jr., Taylor CB, Berkey CS, Frazier AL, Gillman MW, et al. Overweight, weight concerns, and bulimic behaviors among girls and boys. *J Am Acad Child Adolesc Psychiatry*. 1999; 38(6):754-60.
53. Figueroa-Munoz JI, Chinn S, Rona RJ. Association between obesity and asthma in 4-11 year old children in the UK. *Thorax*. 2001; 56(2):133-7.
54. Wright CM, Parker L, Lamont D, Craft AW. Implications of childhood obesity for adult health: findings from thousand families cohort study. *BMJ*. 2001; 323(7324):1280-4.
55. Kahn BB, Flier JS. Obesity and insulin resistance. *J Clin Invest*. 2000; 106(4):473-81.
56. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. Mechanism of free fatty acid-induced insulin resistance in humans. *J Clin Invest*. 1996; 97(12):2859-65.
57. Wilcox G. Insulin and insulin resistance. *Clin Biochem Rev*. 2005; 26(2):19-39.
58. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care*. 2001; 24(4):683-9.
59. Lakka H-M, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men. *JAMA*. 2002 [cited 10/21/2021]; 288(21):2709-2716.
60. Medina-Gomez G, Vidal-Puig A. Gateway to the metabolic syndrome. *Nature Medicine*. 2005; 11(6):602-603.
61. Aschner P, Horton E, Leiter LA, Munro N, Skyler JS. Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management. *Int J Clin Pract*. 2010; 64(3):305-15.
62. Obesity Collaborators. *The Global Burden of Disease*. 2015.
63. Amugsi DA, Dimbuene ZT, Mberu B, Muthuri S, Ezech AC. Prevalence and time trends in overweight and obesity among urban women: an analysis of demographic and health surveys data from 24 African countries, 1991-2014. *BMJ Open*. 2017; 7(10):2017-017344.
64. World Health Organization. 2016.

65. Strain G, Zumoff B, Rosner W, Pi-Sunyer X. Strain G, Zumoff B, Rosner W, Pi-Sunyer X. The relationship between serum levels of insulin and sex hormone-binding globulin in men: the effect of weight loss. *J Clin Endocrinol Metab* 79: 1173-1176. *The Journal of clinical endocrinology and metabolism*. 1994; 79:1173-6.
66. Lee M, Aronne LJ. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. *Am J Cardiol*. 2007; 99(4A):27.
67. Bays HE. "Sick fat," metabolic disease, and atherosclerosis. *Am J Med*. 2009; 122(1 Suppl):S26-37.
68. Wilding JP. The importance of weight management in type 2 diabetes mellitus. *Int J Clin Pract*. 2014; 68(6):682-91.
69. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. *Hepatology*. 2010; 51(2):679-89.
70. Chertow GM, Hsu CY, Johansen KL. The enlarging body of evidence: obesity and chronic kidney disease. *J Am Soc Nephrol*. 2006; 17(6):1501-2.
71. Ting SM, Nair H, Ching I, Taheri S, Dasgupta I. Overweight, obesity and chronic kidney disease. *Nephron Clin Pract*. 2009; 112(3):c121-7; discussion c127.
72. Mount P, Davies M, Choy SW, Cook N, Power D. Obesity-Related Chronic Kidney Disease-The Role of Lipid Metabolism. *Metabolites*. 2015; 5(4):720-32.
73. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. *Nature*. 2001; 414(6865):782-7.
74. Verma S, Hussain ME. Obesity and diabetes: An update. *Diabetes Metab Syndr*. 2017; 11(1):73-79.
75. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. *Am J Epidemiol*. 1997; 146(3):214-22.
76. Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. *Diabetes Metab Syndr Obes*. 2014; 7:587-91.
77. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. *BMC Public Health*. 2009; 9:88.
78. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*. 2006; 444(7121):840-6.

79. Stone NJ, Kushner R. Effects of dietary modification and treatment of obesity. Emphasis on improving vascular outcomes. *Med Clin North Am.* 2000; 84(1):95-122.
80. Wadden TA, Foster GD. Behavioral treatment of obesity. *Med Clin North Am.* 2000; 84(2):441-61, vii.
81. Li M, Cheung BM. Pharmacotherapy for obesity. *Br J Clin Pharmacol.* 2009; 68(6):804-10.
82. Cheung BM, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. *Ther Adv Drug Saf.* 2013; 4(4):171-81.
83. Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety. *Diabetes Metab J.* 2012; 36(1):13-25.
84. Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. *Arch Intern Med.* 2001; 161(15):1814-24.
85. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. *Clin Sci (Lond).* 2012; 122(6):253-70.
86. Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. *Br J Cancer.* 2012; 106(8):1374-8.
87. Zhai J, Liu CX, Tian ZR, Jiang QH, Sun YP. Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. *Biol Reprod.* 2012; 87(2):29.
88. Hindlet P, Barraud C, Boschhat L, Farinotti R, Bado A, Buyse M. Rosiglitazone and metformin have opposite effects on intestinal absorption of oligopeptides via the proton-dependent PepT1 transporter. *Mol Pharmacol.* 2012; 81(3):319-27.
89. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. *Diabetes Care.* 1992; 15(2):193-203.
90. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. *N Engl J Med.* 1994; 331(18):1188-93.
91. Yki-Jarvinen H. Thiazolidinediones. *N Engl J Med.* 2004; 351(11):1106-18.
92. Rendell MS, Kirchain WR. Pharmacotherapy of type 2 diabetes mellitus. *Ann Pharmacother.* 2000; 34(7-8):878-95.

93. Sheehan MT. Current therapeutic options in type 2 diabetes mellitus: a practical approach. *Clin Med Res.* 2003; 1(3):189-200.
94. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. *Metabolism.* 2006; 55(5 Suppl 1):S20-7.
95. Morsink LM, Smits MM, Diamant M. Advances in pharmacologic therapies for type 2 diabetes. *Curr Atheroscler Rep.* 2013; 15(2):302.
96. Perfetti R, Ahmad A. Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin. *Trends Endocrinol Metab.* 2000; 11(6):218-23.
97. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. *J Diabetes Complications.* 2003; 17(2 Suppl):11-5.
98. Bryan J, Crane A, Vila-Carriles WH, Babenko AP, Aguilar-Bryan L. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. *Curr Pharm Des.* 2005; 11(21):2699-716.
99. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA.* 2003; 290(4):486-94.
100. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. *Curr Drug Metab.* 2011; 12(1):57-69.
101. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. *Diabetes.* 2002; 51(4):943-50.
102. Holst JJ. The physiology of glucagon-like peptide 1. *Physiol Rev.* 2007; 87(4):1409-39.
103. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. *Eur J Biochem.* 1993; 214(3):829-35.
104. Bundhun PK, Janoo G, Teeluck AR, Huang F. Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. *BMC Pharmacol Toxicol.* 2017; 18(1):66.

105. Elkinson S, Scott LJ. Canagliflozin: first global approval. *Drugs*. 2013; 73(9):979-88.
106. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab*. 2014; 16(5):457-66.
107. Safavi M, Foroumadi A, Abdollahi M. The importance of synthetic drugs for type 2 diabetes drug discovery. *Expert Opin Drug Discov*. 2013; 8(11):1339-63.
108. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. *Ann Intern Med*. 2005; 142(7):532-46.
109. Adan RA. Mechanisms underlying current and future anti-obesity drugs. *Trends Neurosci*. 2013; 36(2):133-40.
110. Heal DJ, Gosden J, Smith SL. What is the prognosis for new centrally-acting anti-obesity drugs? *Neuropharmacology*. 2012; 63(1):132-46.
111. Hogan S, Fleury A, Hadvary P, Lengsfeld H, Meier MK, Triscari J, et al. Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase. *Int J Obes*. 1987; 11 Suppl 3:35-42.
112. Guerciolini R. Mode of action of orlistat. *Int J Obes Relat Metab Disord*. 1997; 21 Suppl 3:S12-23.
113. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care*. 2004; 27(1):155-61.
114. Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. *Endocrine*. 2006; 29(1):49-60.
115. Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. *Expert Opin Drug Saf*. 2012; 11(3):459-71.
116. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. *Lancet*. 2007; 370(9600):1706-13.
117. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004; 27(5):1047-53.
118. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. *Lancet*. 2011; 378(9786):182-97.

119. Fredriksson R, Hoglund PJ, Gloriam DE, Lagerstrom MC, Schioth HB. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. *FEBS Lett.* 2003; 554(3):381-8.
120. Bonini j, A.borowsky, be. DNA encoding SNORF25 receptor. Google Patents. 2001.
121. JONES CRS, G;. 1, 2, 3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia. Google Patents. 2006.
122. Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S. Identification of G protein-coupled receptor genes from the human genome sequence. *FEBS Lett.* 2002; 520(1-3):97-101.
123. Davey J. G-protein-coupled receptors: new approaches to maximise the impact of GPCRS in drug discovery. *Expert Opin Ther Targets.* 2004; 8(2):165-70.
124. Griffin G. Methods for identification of modulators of OSGPR116 activity. Google Patents. 2006.
125. Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, et al. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. *Endocrinology.* 2008; 149(5):2038-47.
126. Chu ZL, Jones RM, He H, Carroll C, Gutierrez V, Lucman A, et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. *Endocrinology.* 2007; 148(6):2601-9.
127. Costanzi S, Neumann S, Gershengorn MC. Seven transmembrane-spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects. *J Biol Chem.* 2008; 283(24):16269-73.
128. Mo XL, Yang Z, Tao YX. Targeting GPR119 for the potential treatment of type 2 diabetes mellitus. *Prog Mol Biol Transl Sci.* 2014; 121:95-131.
129. Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. *Diabetes.* 2009; 58(5):1058-66.
130. Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. *Diabetologia.* 2009; 52(2):289-298.
131. Soga T, Ohishi T, Matsui T, Saito T, Matsumoto M, Takasaki J, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an

- orphan G-protein-coupled receptor. *Biochem Biophys Res Commun.* 2005; 326(4):744-51.
132. Overton HA, Fyfe MC, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. *Br J Pharmacol.* 2008; 153 Suppl 1:S76-81.
  133. Odori S, Hosoda K, Tomita T, Fujikura J, Kusakabe T, Kawaguchi Y, et al. GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function. *Metabolism.* 2013; 62(1):70-8.
  134. Yang JW, Kim HS, Im JH, Kim JW, Jun DW, Lim SC, et al. GPR119: a promising target for nonalcoholic fatty liver disease. *FASEB J.* 2016; 30(1):324-35.
  135. Zhao J, Zhao Y, Hu Y, Peng J. Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease. *Cell Mol Biol Lett.* 2021; 26(1):32.
  136. Chu ZL, Carroll C, Chen R, Alfonso J, Gutierrez V, He H, et al. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. *Mol Endocrinol.* 2010; 24(1):161-70.
  137. Hansen KB, Rosenkilde MM, Knop FK, Wellner N, Diep TA, Rehfeld JF, et al. 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. *J Clin Endocrinol Metab.* 2011; 96(9):E1409-17.
  138. Lan H, Vassileva G, Corona A, Liu L, Baker H, Golovko A, et al. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. *J Endocrinol.* 2009; 201(2):219-30.
  139. Ekberg JH, Hauge M, Kristensen LV, Madsen AN, Engelstoft MS, Husted AS, et al. GPR119, a Major Enteroendocrine Sensor of Dietary Triglyceride Metabolites Coacting in Synergy With FFA1 (GPR40). *Endocrinology.* 2016; 157(12):4561-4569.
  140. Dhayal S, Morgan NG. The significance of GPR119 agonists as a future treatment for type 2 diabetes. *Drug News Perspect.* 2010; 23(7):418-24.
  141. Semple G, Ren A, Fioravanti B, Pereira G, Calderon I, Choi K, et al. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. *Bioorg Med Chem Lett.* 2011; 21(10):3134-41.
  142. Semple G, Lehmann J, Wong A, Ren A, Bruce M, Shin YJ, et al. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. *Bioorg Med Chem Lett.* 2012; 22(4):1750-5.

143. Roberts B, Gregoire F, Karpf D, Clemens E, Lavan B, Johnson J, et al. MBX-2982, a Novel, Oral GPR119 Agonist for the Treatment of Type 2 Diabetes: Results of Single and Multiple Dose Studies. 2009; p. A43-A43.
144. Kang SU. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119. *Drug Discov Today*. 2013; 18(23-24):1309-15.
145. Oshima H, Yoshida S, Ohishi T, Matsui T, Tanaka H, Yonetoku Y, et al. Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice. *Life Sci*. 2013; 92(2):167-73.
146. Wacker DA, Wang Y, Broekema M, Rossi K, O'Connor S, Hong Z, et al. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. *J Med Chem*. 2014; 57(18):7499-508.
147. Kim SR, Kim DH, Park SH, Kim YS, Kim CH, Ha TY, et al. In vivo efficacy of HD0471953: a novel GPR119 agonist for the treatment of type 2 diabetes mellitus. *J Diabetes Res*. 2013; 2013:269569.
148. Park YH, Choi HH, Lee DH, Chung SY, Yang NY, Kim DH, et al. YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model. *Arch Pharm Res*. 2017; 40(6):772-782.
149. Gao J, Tian L, Weng G, O'Brien TD, Luo J, Guo Z. Stimulating beta-cell replication and improving islet graft function by AR231453, A GPR119 agonist. *Transplant Proc*. 2011; 43(9):3217-20.
150. McKillop AM, Moran BM, Abdel-Wahab YH, Gormley NM, Flatt PR. Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice. *Diabetologia*. 2016; 59(12):2674-2685.
151. Ansarullah, Lu Y, Holstein M, DeRuyter B, Rabinovitch A, Guo Z. Stimulating beta-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor. *PLoS One*. 2013; 8(1):e53345.
152. Ansarullah, Free C, Christopherson J, Chen Q, Gao J, Liu C, et al. Activation of GPR119 Stimulates Human beta-Cell Replication and Neogenesis in Humanized Mice with Functional Human Islets. *J Diabetes Res*. 2016; 2016:1620821.
153. Rodriguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J, et al. An anorexic lipid mediator regulated by feeding. *Nature*. 2001; 414(6860):209-12.

154. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. *Nature*. 1996; 379(6560):69-72.
155. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. *Nature*. 2003; 425(6953):90-3.
156. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. *Eur J Pharmacol*. 2002; 440(2-3):269-79.
157. Nielsen LL. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. *Drug Discov Today*. 2005; 10(10):703-10.
158. Flock G, Holland D, Seino Y, Drucker DJ. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. *Endocrinology*. 2011; 152(2):374-83.
159. Al-Barazanji K, McNulty J, Binz J, Generaux C, Benson W, Young A, et al. Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice. *J Pharmacol Exp Ther*. 2015; 353(3):496-504.
160. Hassing HA, Fares S, Larsen O, Pad H, Hauge M, Jones RM, et al. Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119. *Biochem Pharmacol*. 2016; 119:66-75.
161. Nguyen CA, Akiba Y, Kaunitz JD. Recent advances in gut nutrient chemosensing. *Curr Med Chem*. 2012; 19(1):28-34.
162. Yang JW, Kim HS, Choi YW, Kim YM, Kang KW. Therapeutic application of GPR119 ligands in metabolic disorders. *Diabetes Obes Metab*. 2018; 20(2):257-269.
163. Cornall LM, Mathai ML, Hryciw DH, McAinch AJ. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases? *Expert Opin Investig Drugs*. 2013; 22(4):487-98.
164. Talukdar S, Olefsky JM, Osborn O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. *Trends Pharmacol Sci*. 2011; 32(9):543-50.
165. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). *Pharmacol Rev*. 2010; 62(4):588-631.

166. Moran BM, Flatt PR, McKillop AM. G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homeostasis. *Acta Diabetol.* 2016; 53(2):177-88.
167. Moran BM, Abdel-Wahab YH, Flatt PR, McKillop AM. Activation of GPR119 by fatty acid agonists augments insulin release from clonal beta-cells and isolated pancreatic islets and improves glucose tolerance in mice. *Biol Chem.* 2014; 395(4):453-64.
168. Kogure R, Toyama K, Hiyamuta S, Kojima I, Takeda S. 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion. *Biochem Biophys Res Commun.* 2011; 416(1-2):58-63.
169. Chu CJ, Huang SM, De Petrocellis L, Bisogno T, Ewing SA, Miller JD, et al. N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. *J Biol Chem.* 2003; 278(16):13633-9.
170. Hansen HS, Rosenkilde MM, Holst JJ, Schwartz TW. GPR119 as a fat sensor. *Trends Pharmacol Sci.* 2012; 33(7):374-81.
171. Drzazga A, Kristinsson H, Salaga M, Zatorski H, Koziolkiewicz M, Gendaszewska-Darmach E, et al. Lysophosphatidylcholine and its phosphorothioate analogues potentiate insulin secretion via GPR40 (FFAR1), GPR55 and GPR119 receptors in a different manner. *Mol Cell Endocrinol.* 2018; 472:117-125.
172. Metz SA. Ether-linked lysophospholipids initiate insulin secretion. Lysophospholipids may mediate effects of phospholipase A2 activation on hormone release. *Diabetes.* 1986; 35(7):808-17.
173. Krautbauer S, Eisinger K, Wiest R, Liebisch G, Buechler C. Systemic saturated lysophosphatidylcholine is associated with hepatic function in patients with liver cirrhosis. *Prostaglandins Other Lipid Mediat.* 2016; 124:27-33.
174. Hung ND, Sok DE, Kim MR. Prevention of 1-palmitoyl lysophosphatidylcholine-induced inflammation by polyunsaturated acyl lysophosphatidylcholine. *Inflamm Res.* 2012; 61(5):473-83.
175. Murugesan G, Sandhya Rani MR, Gerber CE, Mukhopadhyay C, Ransohoff RM, Chisolm GM, et al. Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines. *J Mol Cell Cardiol.* 2003; 35(11):1375-84.
176. Hassing HA, Engelstoft MS, Sichlau RM, Madsen AN, Rehfeld JF, Pedersen J, et al. Oral 2-oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor. *Biofactors.* 2016; 42(6):665-673.

177. Thabuis C, Destailats F, Landrier JF, Tissot-Favre D, Martin JC. Analysis of gene expression pattern reveals potential targets of dietary oleoylethanolamide in reducing body fat gain in C3H mice. *J Nutr Biochem*. 2010; 21(10):922-8.
178. Tough IR, Forbes S, Herzog H, Jones RM, Schwartz TW, Cox HM. Bidirectional GPR119 Agonism Requires Peptide YY and Glucose for Activity in Mouse and Human Colon Mucosa. *Endocrinology*. 2018; 159(4):1704-1717.
179. Pavon FJ, Serrano A, Perez-Valero V, Jagerovic N, Hernandez-Folgado L, Bermudez-Silva FJ, et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. *J Neuroendocrinol*. 2008; 20 Suppl 1:116-23.
180. Higuchi S, Ahmad TR, Argueta DA, Perez PA, Zhao C, Schwartz GJ, et al. Bile acid composition regulates GPR119-dependent intestinal lipid sensing and food intake regulation in mice. *Gut*. 2020; 69(9):1620-1628.
181. Hutch CR, Trakimas DR, Roelofs K, Pressler J, Sorrell J, Cota D, et al. Oea Signaling Pathways and the Metabolic Benefits of Vertical Sleeve Gastrectomy. *Ann Surg*. 2020; 271(3):509-518.
182. Semple G, Fioravanti B, Pereira G, Calderon I, Uy J, Choi K, et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. *J Med Chem*. 2008; 51(17):5172-5.
183. Marty VN, Farokhnia M, Munier JJ, Mulpuri Y, Leggio L, Spigelman I. Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats. *Front Neurosci*. 2020; 14:599646.
184. Ali S, Lamont BJ, Charron MJ, Drucker DJ. Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. *J Clin Invest*. 2011; 121(5):1917-29.
185. Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, Xi L, et al. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. *Diabetes Obes Metab*. 2012; 14(8):709-16.
186. Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, Xi L, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects. *Clin Pharmacol Ther*. 2011; 90(5):685-92.
187. Ritter K, Buning C, Halland N, Poverlein C, Schwink L. G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges. *J Med Chem*. 2016; 59(8):3579-92.

188. Faitova J, Krekac D, Hrstka R, Vojtesek B. Endoplasmic reticulum stress and apoptosis. *Cell Mol Biol Lett*. 2006; 11(4):488-505.
189. Zhao J, Hu Y, Peng J. Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy. *Cell Mol Biol Lett*. 2021; 26(1):17.
190. Huan Y, Jiang Q, Li G, Bai G, Zhou T, Liu S, et al. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. *Sci Rep*. 2017; 7(1):4351.
191. Yoshida S, Tanaka H, Oshima H, Yamazaki T, Yonetoku Y, Ohishi T, et al. AS1907417, a novel GPR119 agonist, as an insulinotropic and beta-cell preservative agent for the treatment of type 2 diabetes. *Biochem Biophys Res Commun*. 2010; 400(4):745-51.
192. Cvijanovic N, Isaacs NJ, Rayner CK, Feinle-Bisset C, Young RL, Little TJ. Lipid stimulation of fatty acid sensors in the human duodenum: relationship with gastrointestinal hormones, BMI and diet. *Int J Obes (Lond)*. 2017; 41(2):233-239.
193. Kwon G, Pappan KL, Marshall CA, Schaffer JE, McDaniel ML. cAMP Dose-dependently prevents palmitate-induced apoptosis by both protein kinase A- and cAMP-guanine nucleotide exchange factor-dependent pathways in beta-cells. *J Biol Chem*. 2004; 279(10):8938-45.
194. Koh G, Suh KS, Chon S, Oh S, Woo JT, Kim SW, et al. Elevated cAMP level attenuates 2-deoxy-d-ribose-induced oxidative damage in pancreatic beta-cells. *Arch Biochem Biophys*. 2005; 438(1):70-9.
195. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. *Hepatology*. 2006; 43(1):173-81.
196. Deal watch: Metabolex and Sanofi-Aventis partner on GPCR agonists for type 2 diabetes. *Nat Rev Drug Discov*. 2010; 9(9):670.
197. Gendaszewska-Darmach E, Drzazga A, Koziolkiewicz M. Targeting GPCRs Activated by Fatty Acid-Derived Lipids in Type 2 Diabetes. *Trends Mol Med*. 2019; 25(10):915-929.
198. Jones RM, Leonard JN, Buzard DJ, Lehmann J. GPR119 agonists for the treatment of type 2 diabetes. *Expert Opin Ther Pat*. 2009; 19(10):1339-59.
199. Pola S, Shah SR, Pingali H, Zaware P, Thube B, Makadia P, et al. Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes. *Bioorg Med Chem*. 2021; 35:116071.

200. Marc G, Stana A, Oniga SD, Pirnau A, Vlase L, Oniga O. New Phenolic Derivatives of Thiazolidine-2,4-dione with Antioxidant and Antiradical Properties: Synthesis, Characterization, In Vitro Evaluation, and Quantum Studies. *Molecules*. 2019; 24(11).
201. Marc G, Araniciu C, Oniga SD, Vlase L, Pirnau A, Nadas GC, et al. Design, Synthesis and Biological Evaluation of New Piperazin-4-yl-(acetyl-thiazolidine-2,4-dione) Norfloxacin Analogues as Antimicrobial Agents. *Molecules*. 2019; 24(21).
202. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. *Adv Drug Deliv Rev*. 2001; 46(1-3):27-43.
203. Li P, Wang B, Zhang X, Batt SM, Besra GS, Zhang T, et al. Identification of novel benzothiopyranone compounds against *Mycobacterium tuberculosis* through scaffold morphing from benzothiazinones. *Eur J Med Chem*. 2018; 160:157-170.